858-449-1310 contact@somatek.com

Biologics

Do Cancer Cells Sleep at Night?

The circadian rhythm influences bodily functions in health and disease. The study of biological cycles driven by environmental and genetic factors is an emerging field and some circadian aspects of metabolism have received considerable attention by the public (looking...

read more

Biosimilars

Biologics, especially antibodies, are important cancer therapeutics that have significantly improved outcomes for a number of solid tumors. However, biologics are considerably more costly than small-molecule drugs; in part because they are more complex to manufacture,...

read more

New Approvals for Cancer Treatments

In 2021, FDA approved more than 60 oncology drugs and biologics including dangling accelerated Approvals, drug dosing, new approvals and more. This recently published article coauthored by FDA’s Steven Lemery and Richard Pazdur provides a nice summary of FDA...

read more

Progress Towards Universal Influenza Vaccine

Influenza vaccines typically coax the immune system to generate antibodies that recognize the head of hemagglutinin (HA), a protein that extends outward from the surface of the flu virus. The head is the most accessible regions of HA, making it a good target for the...

read more

The Interesting World of mRNA Vaccines

The Scientist published under the title "Moderna vs. Pfizer: Is There a “Best” mRNA Vaccine?" an interesting summary of the current data on effectiveness of the Pfizer and Moderna mRNA COVID-19 vaccines. As a somewhat accidental member of #team Moderna this helps to...

read more

A New Type of Antibody –

For a long time 5 antibody types have been known in mammals, IgG, IgM, IgA, IgE, and IgD, with IgG being the work horse in biotechnology. So it drew our attention that a group at Duke University has described a new type of anti-glycan antibody that binds to a patch of...

read more

Monoclonal for Alzheimer’s

On Monday FDA approved Biogen’s aducanumab, brand name Aduhelm, through a program called accelerated approval. Aduhelm is the first new medication for Alzheimer’s disease in nearly two decades. FDA’s decision was welcomed by patients and their families as a...

read more

RNA therapeutics

To those developing treatments for oncology, in the gene therapy space and many other fields it seemed for a long time that RNA-based therapies have many attractive properties but somehow just too many obstacles to overcome. Enter recent break-throughs in vaccine...

read more